Powered by

GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017

Mar 01, 2017 - Business Wire

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC. The company and its collaborators at Washington University in St. Louis will highlight data on GMI-1271 , an antagonist of E-selectin, and GMI-1359 , a dual antagonist of E-selectin ...